BiotechTube
Integrated Research Associates

Integrated Research Associates

San Diego, United States· Est.
integratedresearchassociates.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Integrated Research Associates, founded in 2007, is a private biotechnology company operating in both therapeutic development and research reagents. Its core mission is to address unmet medical needs posed by neurovirulent and globally spreading viruses like dengue, Zika, and Japanese encephalitis through drug and vaccine R&D. The company has a dual business model, combining early-stage, pre-clinical therapeutic programs with a commercial portfolio of validated viral antigens and antibodies for the research community. This provides a revenue stream while funding its internal development efforts.

Infectious Disease

Technology Platform

Integrated virology and immunology research engine with in-house capabilities for viral antigen production, monoclonal antibody discovery, and assay validation (ELISA, Western, PRNT).

Opportunities

The growing global threat from flaviviruses (dengue, Zika, JEV) and enteroviruses creates significant unmet medical need and market potential.
The company's dual model of reagent sales provides early revenue and scientific validation, de-risking therapeutic discovery and creating partnership opportunities with larger biopharma firms.

Risk Factors

The company's therapeutic pipeline is at a high-risk, pre-clinical stage with a long path to market.
As a small, private firm, it faces substantial financial risk and may struggle to secure the capital required for clinical development.
It also operates in highly competitive therapeutic areas dominated by large players.

Competitive Landscape

In therapeutics, IRA competes with large vaccine developers (Sanofi, Takeda), non-profits (NIH, WHO initiatives), and other biotechs in the flavivirus space. In reagents, it competes with established commercial suppliers (Merck, ATCC, The Native Antigen Company) and academic core facilities. Differentiation relies on niche expertise and high-quality validation data.

More companies in Biologics / Biosimilars →More companies in United States →